Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs

PSP led Valo Health’s $190 million Series B preferred-equity financing alongside existing and new investors. The aggregate financing supported drug-development programs and Valo’s computational platform. PSP’s individual amount was undisclosed.